Compare

DSIP vs VIP

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

DSIP

1830 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 54% · Mixed 32% · Unfavorable overall 14%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Joint comfort
177
Recovery
167
Digestive comfort
143
Skin appearance
50
Appetite control
106

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Injection site reaction
93
Anxiety
67
Flushing
108
Headache
46
GI discomfort
106

Self-reported dose per injection

Median bucket: 0.6–1 mg · Most common: 0.4–0.6 mg

Reports span 0.05–5 mg

0.05–0.1 mg
7
0.1–0.2 mg
16
0.2–0.4 mg
24
0.4–0.6 mg
27
0.6–1 mg
18
1–2 mg
15
2–3 mg
10
3–5 mg
4

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing34stacking42side effects20dsip13

How repeat users are trending

Among repeat reporters, 64% said they felt similar to their last entry, 34% more positive, and 14% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 32 days · Based on 403 repeat reporters

VIP

1613 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 47% · Mixed 40% · Unfavorable overall 13%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Lean mass
180
Joint comfort
100
Recovery
90
Digestive comfort
44
Skin appearance
173

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Appetite loss
96
Injection site reaction
180
Anxiety
55
Flushing
39
Headache
172

Self-reported dose per injection

Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg

Reports span 0.01–2 mg

0.01–0.025 mg
2
0.025–0.05 mg
10
0.05–0.1 mg
13
0.1–0.2 mg
23
0.2–0.4 mg
27
0.4–0.6 mg
23
0.6–1 mg
13
1–2 mg
9

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing17stacking15side effects13vip21

How repeat users are trending

Among repeat reporters, 57% said they felt similar to their last entry, 45% more positive, and 17% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 19 days · Based on 355 repeat reporters

Sources (14)

Published sources linked on the DSIP and VIP wiki pages.

  1. PubMed

    Delta-sleep-inducing peptide (DSIP): a review

    Graf MV, Kastin AJ. Neuroscience and biobehavioral reviews. 1984

    Source
    Wiki study page →
  2. PubMed

    Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension

    Ghatei MA, Takahashi K, Suzuki H, et al. J Cardiovasc Pharmacol. 2003

    Source
    Wiki study page →
  3. PubMed

    Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo

    Delgado M, Chorny A, Gonzalez-Rey E, et al. J Leukoc Biol. 2005

    Source
    Wiki study page →
  4. PubMed

    Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions

    Delgado M, Ganea D. Amino Acids. 2013

    Source
    Wiki study page →
  5. PubMed

    Vasoactive intestinal peptide: cardiovascular effects

    Henning RJ, Sawmiller DR. Cardiovascular Research. 2001

    Source
    Wiki study page →
  6. PubMed

    Vasoactive intestinal peptide and the mammalian circadian system

    Vosko AM, Schroeder A, Loh DH, et al. General and Comparative Endocrinology. 2007

    Source
    Wiki study page →
  7. PubMed

    New perspectives on vasoactive intestinal polypeptide as a widespread modulator of social behavior

    Kingsbury MA. Current Opinion in Behavioral Sciences. 2015

    Source
    Wiki study page →
  8. ClinicalTrials.gov

    Vasoactive Intestinal Peptide studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  9. PubMed

    The significance of vasoactive intestinal peptide in immunomodulation

    Delgado M, Pozo D, Ganea D. Pharmacological reviews. 2004

    Source
    Wiki study page →
  10. PubMed

    Role of vasoactive intestinal peptide in osteoarthritis

    Jiang W, Wang H, Li YS, et al. Journal of biomedical science. 2016

    Source
    Wiki study page →